Comment
. 2004 May-Jun;2(3):200, 202; author reply 202.
Clarifying the use of erythropoietic agents
- PMID: 15328822
Item in Clipboard
Comment
Clarifying the use of erythropoietic agents
J Support Oncol.
2004 May-Jun.
No abstract available
Comment on
-
Managing hematologic toxicities.J Support Oncol. 2004 Jan-Feb;2(1):65-79. J Support Oncol. 2004. PMID: 15330374 Review.
Similar articles
-
New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.J Support Oncol. 2007 Nov-Dec;5(10):471-3. J Support Oncol. 2007. PMID: 18240668 No abstract available.
-
Utilizing quality of life as a factor in treatment choices for chemotherapy-induced anemia.J Support Oncol. 2005 Nov-Dec;3(6 Suppl 4):20-1. J Support Oncol. 2005. PMID: 16355554 No abstract available.
-
Earlier initiation of treatment recommended in using erythropoietic agents for chemotherapy-induced anemia.J Support Oncol. 2004 Jul-Aug;2(4):319. J Support Oncol. 2004. PMID: 15357515 No abstract available.
-
Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.Strahlenther Onkol. 2008 Mar;184(3):121-36. doi: 10.1007/s00066-008-1841-3. Strahlenther Onkol. 2008. PMID: 18330508 Review.
-
Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.Expert Rev Anticancer Ther. 2008 Jun;8(6):875-85. doi: 10.1586/14737140.8.6.875. Expert Rev Anticancer Ther. 2008. PMID: 18533797 Review.